Medtronic plc announced today the initiation of the REALITY Study (DiRectional AthErectomy
+ Drug-coAted BaLloon to Treat Long, Calcified FemoropopliTeal ArterY Stenoses) to evaluate patient outcomes following adjunctive use of directional atherectomy
and drug-coated balloon (DCB) treatment of patients with symptomatic peripheral arterial disease (PAD) in long, calcified lesions in the superficial femoral artery (SFA) and/or popliteal artery.
RESULTS OF THE VISION IDE TRIAL FOR THE PANTHERIS OCT-GUIDED DIRECTIONAL ATHERECTOMY
SYSTEM Presenter: Arne Schwindt, MD The VISION trial was completed for investigational device exemption (IDE) of the Pantheris optical coherence tomography (OCT)--guided directional atherectomy
system (Avinger, Inc.
One method is directional atherectomy
, which can be employed, for example, by the TurboHawk Plaque Excision System by Coviden (Plymouth, MN).
has received CE Mark approval for Pantheris a system that combines directional atherectomy
capabilities with real-time intravascular visualization to remove plaque from blocked arteries.
The DEFINITIVE AR study is designed to evaluate the effect of treating a diseased vessel with a combination therapy that begins with directional atherectomy
to remove plaque build-up, followed by the use of a drug-coated balloon that releases anti-proliferative medication to inhibit restenosis.
Covidien pl c Research Reports On November 4, 2014, Covidien plc (Covidien) announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy
followed by drug coated balloon.
Study Confirms Effectiveness of Directional Atherectomy
with SilverHawk [TM] and TurboHawk [TM] Devices as a Frontline Therapy when Treating PAD
It was designed to assess the effect of treating a lesion with directional atherectomy
(Covidien's SilverHawk or TurboHawk plaque excision systems) followed by a paclitaxel-coated balloon (Bayer HealthCare's peripheral paclitaxel-coated angioplasty catheter with Paccocath technology), collectively referred to as DAART (directional atherectomy
+ antirestenotic therapy), in order to generate early hypotheses for further research in this therapy area.
Zad 32 - The directional atherectomy
Today's announcement, coupled with our recently announced joint development of guided directional atherectomy
, is further indication of HP's commitment to the interventional market.
Over 270,000 atherectomy procedures have been performed with the market leading SilverHawk and TurboHawk(TM) directional atherectomy
catheters, uniquely designed to direct the therapy specifically to the diseased portion of the vessel while avoiding healthy portions of the vessel.
OmniCath(r) is a directional atherectomy
catheter that employs deflecting non-traumatizing wires to anchor the cutting window at the atherectomy site.